Developing rapid-acting entactogens for neuropsychiatric conditions

Transcend Therapeutics is a clinical-stage pharmaceutical company advancing methylone, a rapid-acting and non-hallucinogenic MDMA analogue, for PTSD, depression, and other CNS disorders. Transcend is transforming the standard of care for neuropsychiatric conditions through robust, rapid-acting, and durable improvements in neuroplasticity and clinical efficacy across their clinical pipeline.